📍Thought provoking end to the Lynn Sage Breast Cancer Symposium discussing the goals of de-escalation in low risk, escalation in high risk, and individualized treatment in intermediate risk patients. Thankful for the opportunity to attend!✨#LSBC25 @luriecancer.bsky.social

💡Fabulous first day of the Lynn Sage Breast Cancer Symposium discussing obesity, sustainability, breast reconstruction, pathology, AI in oncology, approaches to management cans so much more ✨Thank you Lynn Sage for the travel award!💐 #LSBC25 @luriecancer.bsky.social

Yale Heme/Onc fellows riding for our patients, families, and cancer research 🧬 at the 15th annual Closer to Free Ride! 🚴🏼‍♀️💨 @ctfride.bsky.social @yalecancer.bsky.social

📍HER2+ T-DXd+P is likely the new 1L SOC but many questions remain in HR+ pts, QOL, & potential maintenance strategies
📍TNBC SG+pembro likely new 1L SOC but we need more therapies for these patients

Amazing talk #ASCO2025 Highlights in MBC @maryamlustberg.bsky.social @yalecancer.bsky.social
📍HR+ multiple targeted agents now available, optimal sequencing remains unclear, we need to study in combinations

🚨Practice changing interim results DESTINY-Breast09 evaluating 1st Line T-DXd + P vs THP in HER2+ MBC
🔹PFS 40.7 m vs 26.9 m!
🔹PFS2 not reached vs 36.5 m
🔹 OS immature
#ASCO2025

Lots of buzz around TBCRC 040 PREDICT-DNA trial presented by Dr. Natasha Hunter 🐝 ➰
➡️ Among pts w/ Stg II-III HER2+ & TNBC receiving NAT ctDNA may be may be a better biomarker than pCR for longterm outcomes 🧬
🔸54% ctDNA <100 ppm after NAT
🔸NPV for residual disease 60%

Inspirational words on positioning yourself for success by these four women physician leaders! Sharing advice with early career women in oncology. Now we have the tools for success🛠️✨#ASCO2025 @maryamlustberg.bsky.social @drgattimays.bsky.social @yalecancer.bsky.social

Outstanding talk by Dr. Ian Krop on antibody drug conjugates in the era of targeted therapies. 🔬So much groundbreaking work has been done and there’s still more work to do in understanding mechanism, mechanisms of resistance, and biomarkers for response📈📌 #ASCO2025

Impressive & practice changing ASCENT-04/KEYNOTE-D19 evaluating sacituzumab go ite an + pembro vs chemo + pembro in 1st Line PDL1+ metastatic TNBC demonstrating PFS 11.2 vs 7.8 months! 🚨Much needed improvement in 1st Line metastatic TNBC #ASCO2025

Great start to #ASCO2025 with Yale Cancer Center and at the @conquercancer.bsky.social
Awards Ceremony🏆 So grateful to have the opportunity to research improved biomarkers for ADC response in patients with HER2-low, HER2-ultralow, and HER2 0 breast cancer 🔬🩺